Last reviewed · How we verify
Placebo (for D086)
Placebo (for D086) is a Small molecule drug developed by Chong Kun Dang Pharmaceutical. It is currently in Phase 3 development for Control arm in phase 3 trial for D086 (indication unknown).
Placebo has no active pharmacological mechanism and serves as a control comparator in clinical trials.
Placebo has no active pharmacological mechanism and serves as a control comparator in clinical trials. Used for Control arm in phase 3 trial for D086 (indication unknown).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Placebo (for D086) |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used in randomized controlled trials to establish the efficacy of an investigational drug (D086) by comparison. It contains no active pharmaceutical ingredient and relies on the placebo effect—the measurable improvement in symptoms due to patient expectation and the therapeutic context—to establish a baseline for efficacy assessment.
Approved indications
- Control arm in phase 3 trial for D086 (indication unknown)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for D086) CI brief — competitive landscape report
- Placebo (for D086) updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI
Frequently asked questions about Placebo (for D086)
What is Placebo (for D086)?
How does Placebo (for D086) work?
What is Placebo (for D086) used for?
Who makes Placebo (for D086)?
What development phase is Placebo (for D086) in?
Related
- Manufacturer: Chong Kun Dang Pharmaceutical — full pipeline
- Indication: Drugs for Control arm in phase 3 trial for D086 (indication unknown)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing